Recently Launched Antipsychotic Drug
The concept of targeted therapies remains a holy grail for the pharmaceutical drug industry for identifying responder populations or new drug targets. Here we provide quantitative systems pharmacology as an alternative to the more traditional approach of retrospective responder pharmacogenomics analysis and applied this to the case of iloperidone in schizophrenia.
Background
- Challenge to increase uptake of new antipsychotic in market
- Identifying responder population by traditional PGX
- Understanding the biology of identified SNP
Proposed Quantitative Systems Pharmacology Solution
- Keep drug pharmacology model, allow biological coupling parameters to vary and identify processes that drive difference between placebo and experimental drug
- Rank-order processes using Pareto-plots
Outcome: Geerts (2015)
- QSP platform identified one of the five SNP as driving the model outcome for new investigative drug
- QSP model provided biological explanationwe provide quantitative systems pharmacology as an alternative to the more traditional approach of retrospective responder pharmacogenomics analysis and applied this to the case of iloperidone in schizophrenia. of the Responder SNP